Abstract
Treatment-resistant depression is a pleomorphic phenomenon occurring in 30% of patients with depression. The chance to achieve remission decreases with every subsequent episode. It constitutes a significant part of the global disease burden, causes increased morbidity and mortality, and is associated with poor quality of life. It involves multiple difficult-to-treat episodes, with increasing resistance over time. The concept of staging captures the process of changes causing increasing treatment resistance and global worsening of functioning in all areas of life. Ketamine is a novel rapid-acting antidepressant with neuroplastic potential. Here, we argue that ketamine use as an add-on treatment of resistant major depressive disorder, based on its unique pharmacological properties, can reverse this process, give hope to patients, and prevent therapeutic nihilism.
Funder
Medical University of Gdańsk
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference89 articles.
1. The economic cost of brain disorders in Europe;Eur. J. Neurol.,2012
2. The impact of treatment-resistant depression on health care utilization and costs;J. Clin. Psychiatry,2002
3. The cost burden of treatment resistance in patients with depression;Am. J. Manag. Care,2010
4. The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: Retrospective analysis of population-based registers;BMJ,2013
5. Real-world evidence from a European cohort study of patients with treatment-resistant depression: Baseline patient characteristics;J. Affect. Disord.,2021
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献